Hvordan identifisere personer med høy risiko for kardiovaskulær sykdom?
Hovedbudskap
-
Risiko for koronarsykdom kan estimeres ut fra tabeller hvor alder, kjønn, systolisk blodtrykk, totalkolesterolnivå, røykevaner og eventuell forekomst av diabetes inngår
-
Ved moderat og høy risiko er det viktig å fremme ikke-farmakologiske tiltak som kan redusere risikoen
-
Om risikoen forblir moderat til høy, kan utvidede tester utføres og gi sikrere anslag for personens risiko
-
Om risikoen vedvarende anslås til å ligge over 20 %, må også farmakologisk risikoreduserende behandling vurderes
- 1.
Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Eur Heart J 1997; 18: 1231 – 48.
- 2.
Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1443 – 503.
- 3.
Bjartveit K, Wøien G. Risikofaktorer for hjerte-karsykdom i Norge. Resultater fra undersøkelsen i 18 fylker. Oslo: Statens helseundersøkelser, 1997.
- 4.
UK lies behind many European countries in reducing deaths from heart disease. BMJ 2003; 326: 242.
- 5.
Sigfusson N, Sigurdsson G, Agnarsson U, Gudmundsdottir I, Stefansdottir I, Sigvaldason H et al. Declining coronary heart disease mortality in Iceland: contribution by incidence, recurrence and case fatality rate. Scand Cardiovasc J 2002; 36: 337 – 41.
- 6.
Folkehelseinstituttet. Helseundersøkelser. www.fhi.no/tema/helseundersokelse/oslo (28.5.2003).
- 7.
Folkehelseinstituttet. Helseundersøkelser. www.fhi.no/tema/helseundersokelse/oppland_hedmark/ (28.5.2003).
- 8.
Vaage OF. Mer fritid, mindre husholdsarbeid. Samfunnsspeilet 2002; 4 – 5: 2 – 8.
- 9.
Midthjell K, Krüger O, Holmen J, Tverdal A, Claudi T, Bjørndal A et al. Rapid changes in the prevalence of obesity and known diabetes in an adult Norwegian population. The Nord-Trøndelag Health Surveys: 1984 – 1986 and 1995 – 1997. Diabetes Care 1999; 22: 1813 – 20.
- 10.
Reikvam A, Hagen TP. Markedly changed age distribution among patients hospialized for acute myocardial infarction. Scand Cardiovasc J 2002; 36: 221 – 4.
- 11.
Lackland DT, Egan BM, Colwell J, Feussner J. The impact of hypertension and diabetes on stroke hospitalization. Abstrakt American Society of Hypertension 18th Annual Scientific Meeting – 2003; P-477. New York: American Society of Hypertension, 2003.
- 12.
Kjeldsen SE, Julius S, Hedner T, Hansson L: Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Press 2001; 10: 190 – 2.
- 13.
Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment panel III). JAMA 2001; 285: 2486 – 97.
- 14.
Hjermann I, Byre KV, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Lancet 1981; 2: 1303 – 10.
- 15.
Toop L, Richards D. Preventing cardiovascular disease in primary care. BMJ 2001; 323: 246 – 7.
- 16.
Tonstad S, Westheim A. Implementation of guidelines to screen relatives of patients with premature coronary heart disease in a hospital setting. Am J Cardiol 2002; 90: 1211 – 4.
- 17.
Fox KF. Familial hypercholesterolaemia-screening is effective, but is it cost effective? Eur Heart J 2002; 23: 1892 – 3.
- 18.
Fuggeli P, Solbakk JH. Sunnhetspolitiet umyndiggjør folket. Aftenposten (morgenutgave) 2.5.2003.
- 19.
Green R, Kwok S, Durrington PN. Preventing cardiovascular disease in hypertension: effects of lowering blood pressure and cholesterol. Q J Med 2002; 95: 821 – 6.
- 20.
Wood D. Guidelines and global risk: a European perspective. Eur Heart J 2002; 4 (suppl F): F12 – 8.
- 21.
Wiseth R, Otterstad JE, Haugstvedt Y, Tverdal A, Madsen S, Hjermann I et al. Forebyggelse av koronar hjertesykdom i klinisk praksis. Hjerteforum 2000; 13 (suppl 4): 3 – 62.
- 22.
Andresdottir MB, Sigurdson G, Sigvaldason H, Gudnason V. Fifteen percent of myocardial infarctions and coronary revascularizations explained by family history unrelated to conventional risk factors. Eur Heart J 2002; 23: 1655 – 63.
- 23.
Pearson TA. New tools for coronary risk assessment. What are their advantages and limitations? Circulation 2002; 105: 886 – 92.
- 24.
Newman AB, Manolio TA, Cushman M, Mittelmark M, Polak JF, Powe NR et al. Ankle arm index as a predictor of cardiovacular disease and mortality in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999; 19: 538 – 45.
- 25.
Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Comittee to update the 1997 exercise guidelines). Circulation 2002; 106: 1883 – 92.
- 26.
Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499 – 511.
- 27.
Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363 – 9.
- 28.
Mukherjee D, Yadav JS. Carotid artery intimal-media thickness: indicator of atherosclerotic burden and respons to risk factor modification. Am Heart J 2002; 144: 753 – 9.
- 29.
Tonstad S. Bør behandling av risikofaktorer for hjerte- og karsykdom styres kun av absolutt risiko? Tidsskr Nor Lægeforen 1998; 19: 2966 – 8.
- 30.
Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Parikka PI et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1342 – 50.
- 31.
Knowler WC, and The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393 – 403.
- 32.
Tonstad S, Farsang C, Klaene G, Lewis K, Manolis A, Perruchoud AP et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomized study. Eur Heart J 2003; 24: 946 – 55.
- 33.
Yanowski S, Yanowski JA. Obesity. N Engl J Med 2002; 346: 591 – 602.
- 34.
MRC/BHF heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7 – 22.
- 35.
Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practise. Lancet 2001; 357: 89 – 95.
- 36.
The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145 – 53.